삼일제약

000520KOSPI

41.0 / 100

Reference Date: 2026-09-08

Financial Score15.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 10.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Samil Pharmaceutical, established in 1947, is a mid-sized pharmaceutical company specializing in ophthalmology, epilepsy, and digestive system drugs, with a business structure focused on original and generic drug development, production, and sales. In 2025, its consolidated sales reached 210.3 billion won, and it has secured domestic sales rights for NASH treatment 'Aramchol' and osteoarthritis treatment 'Lorecivivint', while also completing a global ophthalmology CMO plant in Vietnam.

Number of Employees

614people

Average Salary

67.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.02Industry Average 1.204.0Point

In line with industry avg

ROE

-22.41Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

39.90Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼9923.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.3% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 6,280Won52-week high 12,31052-week low 5,830

1-month return1.0Point

1m -10.29% (falling)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14